BioTuesdays

Category - Markets

Orchard Therapeutics Logo
Markets

JP Morgan starts Orchard Therapeutics at OW; PT $25

JP Morgan launched coverage of Orchard Therapeutics (NASDAQ:ORTX) with an “overweight” rating and December 2019 price target of $25. The stock closed at $16.75 on Nov. 22. Analyst Anupam Rama writes that Orchard, in a...

November 26, 2018
Audentes
Markets

JP Morgan starts Audentes Therapeutics at OW; PT $35

JP Morgan initiated coverage on Audentes Therapeutics (NASDAQ:BOLD) with an “overweight” rating and December 2019 price target of $35. The stock closed at $23.91 on Nov. 22. “Audentes shares have pulled back 40%-plus...

November 26, 2018
Helius Medical Technologies Logo
Markets

BTIG ups Helius Medical to buy; PT $14

BTIG upgraded Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) to “buy” from “neutral,” with a $14 price target, after the company closed a $17.5-million stock offering. The stock closed at $8 on Nov. 19. Analyst Dr...

November 21, 2018
Bellus Health Logo
Markets

Mackie ups Bellus Health PT to $2.20 from $1

Mackie Research raised its price target for Bellus Health (TSX:BLU) to $2.20 from $1 after the company reported Phase 1 top-line results of BLU-5937 for the treatment of chronic cough. In the study, BLU-5937...

November 20, 2018
Assembly Biosciences
Markets

Leerink starts Assembly Biosciences at OP; PT $45

Leerink Partners launched coverage of Assembly Biosciences (NASDAQ:ASMB) with an “outperform” rating and $45 price target. The stock closed at $24.67 on Nov. 16. “Our valuation and rating are based on our probability...

November 19, 2018
AC Immune
Markets

Leerink starts AC Immune at OP; PT $18

Leerink Partners initiated coverage of AC Immune (NASDAQ:ACIU) with an “outperform” rating and price target of $18. The stock closed at $9.65 on Nov. 15. AC Immune develops medicines and diagnostic tools for...

November 16, 2018
Adamas Pharmaceuticals Logo
Markets

Leerink starts Adamas Pharma at OP; PT $20

Leerink Partners launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with an “outperform” rating and $20 price target. The stock closed at $10.84 on Nov. 15. Adamas applies its drug delivery technology to improve...

November 16, 2018